Home Industry Reports Custom Research Blogs About Us Contact us

Hereditary Angioedema Treatment Market Size & Share, By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor), Route of Administration (Intravenous (IV), Subcutaneous Injections), Distribution Channel (Hospital Pharmacy, Retail Pharmacy),, Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Report ID: FBI 3549


Published Date: May-2024


Format : PDF, Excel

Market Outlook:

Hereditary Angioedema Treatment Market size crossed USD 4.71 Billion in 2023 and is set to reach USD 17.91 Billion by end of the year 2032, observing around 16% CAGR between 2024 and 2032.

Base Year Value (2023)

USD 4.71 Billion

19-23 x.x %
24-32 x.x %

CAGR (2024-2032)


19-23 x.x %
24-32 x.x %

Forecast Year Value (2032)

USD 17.91 Billion

19-23 x.x %
24-32 x.x %
Hereditary Angioedema Treatment Market

Historical Data Period


Hereditary Angioedema Treatment Market

Largest Region

North America

Hereditary Angioedema Treatment Market

Forecast Period


Get more details on this report -

Market Dynamics:

Growth Drivers & Opportunities:

1. Increasing Awareness and Diagnosis Rate:

One of the major growth drivers for the Hereditary Angioedema (HAE) treatment market is the increasing awareness and diagnosis rate of the condition. As medical professionals and patients become more informed about HAE, there is a growing demand for treatment options, which is driving the market growth.

2. Technological Advancements in Treatment Options:

The development of advanced treatment options, such as new drug formulations and targeted therapies, is another key driver for the HAE treatment market. Technological advancements are leading to the introduction of more effective and personalized treatments, which is fueling the market growth.

3. Rising Healthcare Expenditure:

The increasing healthcare expenditure, particularly in developing economies, is creating opportunities for the growth of the HAE treatment market. As healthcare infrastructure improves and access to healthcare services expands, more patients with HAE are seeking treatment, driving the market growth.

4. Increasing Research and Development Activities:

The growing investment in research and development activities for HAE treatment is also contributing to market growth. With a focus on developing novel therapies and improving existing treatment options, the market is expected to experience significant growth in the coming years.

Report Scope

Report CoverageDetails
Segments CoveredDrug Class, Route of Administration, Distribution Channel
Regions Covered• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company ProfiledShire plc, Sanofi, Pharming Healthcare,, Attune Pharmaceuticals, Adverum Biotechnologies, Pharming Group N.V, Arrowhead Pharmaceuticals.

Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!

Industry Restraints:

1. High Cost of Treatment:

The high cost associated with HAE treatment is a major restraint for market growth. The expenses related to long-term treatment, including medication and hospital visits, can be a significant burden for patients and healthcare systems, limiting market expansion.

2. Limited Access to Treatment:

Limited access to HAE treatment, particularly in rural and underserved areas, is another major restraint for the market. Access to specialized healthcare facilities and medication can be a challenge for some patients, hindering market growth.

3. Adverse Effects of Treatment:

The potential for adverse effects and complications from HAE treatment is a significant restraint for market growth. Concerns about safety and side effects may deter some patients from seeking treatment, impacting the overall market growth.

Regional Forecast:

Hereditary Angioedema Treatment Market

Largest Region

North America

XX% Market Share by 2032

Get more details on this report -

North America:

The hereditary angioedema treatment market in North America is expected to experience significant growth due to the high prevalence of hereditary angioedema in the United States and Canada. The presence of well-established healthcare infrastructure and increasing awareness about hereditary angioedema among patients and healthcare professionals in the region are also contributing to market growth. Additionally, the presence of key market players and ongoing research and development activities are driving the market in North America.

Asia Pacific:

In Asia Pacific, the hereditary angioedema treatment market is projected to show substantial growth, particularly in countries like China, Japan, and South Korea. The increasing prevalence of hereditary angioedema in the region, along with the rising healthcare expenditure and growing awareness about the disease, are driving market growth. Moreover, the expanding pharmaceutical industry and improving access to advanced treatment options are further fueling the market in Asia Pacific.


The hereditary angioedema treatment market in Europe, specifically in the United Kingdom, Germany, and France, is expected to witness significant growth due to the increasing prevalence of hereditary angioedema and the presence of advanced healthcare infrastructure in these countries. Furthermore, the availability of novel therapies and the presence of key market players driving research and development activities are contributing to the growth of the market in Europe.

Report Coverage & Deliverables

Historical Statistics Growth Forecasts Latest Trends & Innovations Market Segmentation Regional Opportunities Competitive Landscape
Hereditary Angioedema Treatment Market
Hereditary Angioedema Treatment Market

Segmentation Analysis:


In terms of segmentation, the global hereditary angioedema treatment market is analyzed on the basis of Drug Class, Route of Administration, Distribution Channel.

Segment Analysis of Hereditary Angioedema Treatment Market

Drug Class:

The drug class segment of the hereditary angioedema treatment market refers to the different categories of medications used to manage the symptoms of the condition. This segment includes various classes of drugs such as C1 esterase inhibitor, bradykinin receptor antagonist, and kallikrein inhibitor. Each of these drug classes works in different ways to either prevent or treat angioedema attacks, providing healthcare professionals with a range of options for managing the condition.

Route of Administration:

The route of administration segment of the hereditary angioedema treatment market focuses on the different methods by which medications are delivered to patients. This includes oral administration, subcutaneous injection, and intravenous infusion. The choice of route of administration can impact the effectiveness and convenience of treatment for patients, as well as the frequency and timing of medication doses. Healthcare providers must consider various factors such as patient preference, ease of administration, and the specific drug being used when determining the most suitable route of administration for each individual.

Distribution Channel:

The distribution channel segment of the hereditary angioedema treatment market encompasses the various channels through which medications are distributed to patients. This includes hospital pharmacies, retail pharmacies, and online pharmacies. The choice of distribution channel can influence the availability and accessibility of medications for patients, as well as affect the cost and convenience of obtaining treatment. Healthcare providers and pharmaceutical companies must consider the most effective distribution channels for making hereditary angioedema treatments readily available to those in need.

Get more details on this report -

Competitive Landscape:

The competitive landscape in the Hereditary Angioedema Treatment Market is driven by the presence of several key players striving to gain a competitive edge in the market. These players are focusing on research and development to introduce new and effective treatment options for hereditary angioedema. Furthermore, they are also concentrating on strategic collaborations, partnerships, and acquisitions to expand their market presence. The market is characterized by intense competition, with key players vying for market share by offering innovative products and services.

Top Market Players:

1. Shire

2. CSL Behring

3. BioCryst Pharmaceuticals

4. Pharming Group NV

5. iBio, Inc.

6. Ionis Pharmaceuticals

7. KalVista Pharmaceuticals

8. Takeda Pharmaceutical Company Ltd.

9. Attune Pharmaceuticals

10. Pharming Healthcare Inc.

Our Clients

Why Choose Us

Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.

Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.

Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.

Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.

Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.

Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.

Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.

Select Licence Type

Single User

US$ 4250

Multi User

US$ 5050

Corporate User

US$ 6150

Hereditary Angioedema Treatment Market Size & Shar...

RD Code : 24